Professor Ofer Mandelboim of the Hebrew University in Jerusalem has won the 2015 Kaye Innovation for discovering that blocking the NKp46 receptor on Natural Killer cells delays or prevents the onset of Type 1 (Juvenile) Diabetes. Israel’s BioLineRX developed BL-9020 to target NKp46.

http://new.huji.ac.il/en/article/26933